<DOC>
	<DOCNO>NCT00807495</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 study alisertib a/k/a MLN8237 patient relapse refractory non-hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study Alisertib ( MLN8237 ) Adults With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 1 . Patients must histological cytological diagnosis hematological malignancy follow type relapse refractory prior therapy : Diffuse large Bcell lymphoma Mantle cell lymphoma Burkitt 's lymphoma Precursor Blymphoblastic leukemia/lymphoma Tcell lymphoma , exclude primary cutaneous Tcell lymphoma Transformed follicular lymphoma ≥ 50 % diffuse large cell component 2 . Male female patient 18 year old 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 4 . Measurable disease Exclusion criterion include follow : 1 . Pregnant lactating female 2 . Known human immunodeficiency virus ( HIV ) positive AIDSrelated illness 3 . Any serious medical psychiatric illness could interfere completion treatment 4 . Total bilirubin ≥ 1.5 × upper limit normal ( ULN ) 5 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 × ULN . AST , ALT may elevate 5 time ULN elevation reasonably ascribe underlying hematological disorder . 6 . Absolute neutrophil count ( ANC ) &lt; 1,250/mm3 7 . Platelet count &lt; 75,000/mm3 8 . Calculated creatinine clearance &lt; 30 mL/minute 9 . Autologous stem cell transplant le 6 month prior enrollment 10 . Patients undergone allogeneic stem cell organ transplantation 11 . Systemic antineoplastic therapy within 14 day precede first dose study drug treatment 12 . Patients receive treatment nitrosoureas , mitomycin C , rituximab , alemtuzumab , unconjugated antibody treatment , within 42 day 13 . Patients receive treatment radioimmunoconjugates within 12 week 14 . Patients receive radiotherapy within 21 day prior first dose 15 . Myocardial infarction within 6 month enrollment current history New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia 16 . Major surgery within 14 day prior first dose 17 . Infection require systemic antibiotic therapy within 14 day prior first dose serious infection 18 . Clinically uncontrolled central nervous system ( CNS ) involvement . 19 . Inability swallow capsule 20 . History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>MLN8237</keyword>
	<keyword>alisertib</keyword>
</DOC>